PROTEGO Study Protocol: A Cluster Randomised Crossover Trial of Vernix Caseosa Retention for Primary Prevention of Atopic Dermatitis
- 11 October 2026
- journal article
- research article
- Published by Wiley in Clinical & Experimental Allergy
Abstract
Summary: PROTEGO is a Chilean cluster‐randomised crossover trial of vernix caseosa retention to prevent atopic dermatitis. 1383 mother‐infant dyads will be enrolled and followed for atopic dermatitis until 12 months.Keywords
Funding Information
- Agencia Nacional de Investigación y Desarrollo (1241933)
This publication has 7 references indexed in Scilit:
- Vernix Caseosa: Benefits and Clinical Implications in Neonatal Care; A Study Conducted at Almak Nimr University Hospital, Shendi, SudanInternational Journal of Environmental Sciences, 2025
- Atopic Dermatitis in Latin America: A Roadmap to Address Data Collection, Knowledge Gaps, and ChallengesDermatitis®, 2022
- Diagnosing atopic dermatitis in infancy using established diagnostic criteria: a cohort studyBritish Journal of Dermatology, 2021
- Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trialThe Lancet, 2020
- Atopic DermatitisNew England Journal of Medicine, 2008
- Vernix caseosa as a multi-component defence system based on polypeptides, lipids and their interactionsCellular and Molecular Life Sciences, 2005
- Vernix Caseosa in Neonatal AdaptationJournal of Perinatology, 2005